Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy

Authors: Masami Ito, Seiji Niho, Keiji Nihei, Kiyotaka Yoh, Hironobu Ohmatsu, Yuichiro Ohe

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

The purpose of this study was to identify the risk factors associated with fatal pulmonary hemorrhage (PH) in patients with locally advanced non-small cell lung cancer (NSCLC), treated with chemoradiotherapy.

Methods

The medical records of 583 patients with locally advanced NSCLC, who were treated with chemoradiotherapy between July 1992 and December 2009 were reviewed. Fatal PH was defined as PH leading to death within 24 h of its onset. Tumor cavitation size was defined by the cavitation diameter/tumor diameter ratio and was classified as minimum (< 0.25), minor (≥ 0.25, but < 0.5), and major (≥ 0.5).

Results

Of the 583 patients, 2.1% suffered a fatal PH. The numbers of patients with minimum, minor, and major cavitations were 13, 11, and 14, respectively. Among the 38 patients with tumor cavitation, all 3 patients who developed fatal PH had major cavitations. On multivariate analysis, the presence of baseline major cavitation (odds ratio, 17.878), and a squamous cell histology (odds ratio, 5.491) proved to be independent significant risk factors for fatal PH. Interestingly, all patients with fatal PH and baseline major cavitation were found to have tumors with squamous cell histology, and the occurrence of fatal PH in patients having both risk factors was 33.3%.

Conclusions

Patients at high risk of fatal PH could be identified using a combination of independent risk factors.
Literature
1.
go back to reference Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Canc. 1996, 88: 1210-1215. 10.1093/jnci/88.17.1210.CrossRef Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Canc. 1996, 88: 1210-1215. 10.1093/jnci/88.17.1210.CrossRef
2.
go back to reference Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Ins. 1995, 87: 198-205. 10.1093/jnci/87.3.198.CrossRef Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Ins. 1995, 87: 198-205. 10.1093/jnci/87.3.198.CrossRef
3.
go back to reference Sandler AB, Schiller JH, Gray R, et al: Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced resectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol. 2009, 27: 1405-1412. 10.1200/JCO.2008.16.2412. Epub 2009 Feb 17. Erratum in: J Clin Oncol, 2009, 27(20):3410CrossRefPubMedPubMedCentral Sandler AB, Schiller JH, Gray R, et al: Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced resectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol. 2009, 27: 1405-1412. 10.1200/JCO.2008.16.2412. Epub 2009 Feb 17. Erratum in: J Clin Oncol, 2009, 27(20):3410CrossRefPubMedPubMedCentral
4.
go back to reference Panos RJ, Barr LF, Walsh TJ, et al: Factors associated with fatal hemoptysis in cancer patients. Chest. 1998, 94 (5): 1008-1013.CrossRef Panos RJ, Barr LF, Walsh TJ, et al: Factors associated with fatal hemoptysis in cancer patients. Chest. 1998, 94 (5): 1008-1013.CrossRef
5.
go back to reference Isaacs RD, Wattie WJ, Wells AU, et al: Massive haemoptysis as a late consequence of pulmonary irradiation. Thorax. 1987, 42 (1): 77-78. 10.1136/thx.42.1.77.CrossRefPubMedPubMedCentral Isaacs RD, Wattie WJ, Wells AU, et al: Massive haemoptysis as a late consequence of pulmonary irradiation. Thorax. 1987, 42 (1): 77-78. 10.1136/thx.42.1.77.CrossRefPubMedPubMedCentral
6.
go back to reference Makker HK, Barnes PC: Fatal haemoptysis from the pulmonary artery as a late complication of pulmonary irradiation. Thorax. 1991, 46 (8): 609-610. 10.1136/thx.46.8.609.CrossRefPubMedPubMedCentral Makker HK, Barnes PC: Fatal haemoptysis from the pulmonary artery as a late complication of pulmonary irradiation. Thorax. 1991, 46 (8): 609-610. 10.1136/thx.46.8.609.CrossRefPubMedPubMedCentral
7.
go back to reference Miller RR, McGregor DH: Hemorrhage from carcinoma of the lung. Cancer. 1980, 46 (1): 200-205. 10.1002/1097-0142(19800701)46:1<200::AID-CNCR2820460133>3.0.CO;2-V.CrossRefPubMed Miller RR, McGregor DH: Hemorrhage from carcinoma of the lung. Cancer. 1980, 46 (1): 200-205. 10.1002/1097-0142(19800701)46:1<200::AID-CNCR2820460133>3.0.CO;2-V.CrossRefPubMed
8.
go back to reference Balducci L: Geriatric oncology: challenges for the new century. Eur J Cancer. 2000, 36 (14): 1741-1754. 10.1016/S0959-8049(00)00169-6.CrossRefPubMed Balducci L: Geriatric oncology: challenges for the new century. Eur J Cancer. 2000, 36 (14): 1741-1754. 10.1016/S0959-8049(00)00169-6.CrossRefPubMed
9.
go back to reference UICC: TNM Classification of Malignant Tumors. Edited by: Sobin LH, Wittekind CH. 2002, New York: Wiley, 99-103. 6 UICC: TNM Classification of Malignant Tumors. Edited by: Sobin LH, Wittekind CH. 2002, New York: Wiley, 99-103. 6
10.
go back to reference Travis WD, Brambilla E, Muller-Hermelink HK, et al: World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. 2004, Lyon: IARC Travis WD, Brambilla E, Muller-Hermelink HK, et al: World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. 2004, Lyon: IARC
11.
go back to reference Friedel G, Budach W, Dippon J, et al: Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol. 2010, 28 (6): 942-948. 10.1200/JCO.2008.21.7810. Epub 2010 Jan 25CrossRefPubMed Friedel G, Budach W, Dippon J, et al: Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol. 2010, 28 (6): 942-948. 10.1200/JCO.2008.21.7810. Epub 2010 Jan 25CrossRefPubMed
12.
go back to reference Robinson LA, Ruckdeschel JC, Wagner H, et al: American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelined. Chest. 2007, 132 (Suppl 3): 243S-265S. 2CrossRefPubMed Robinson LA, Ruckdeschel JC, Wagner H, et al: American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelined. Chest. 2007, 132 (Suppl 3): 243S-265S. 2CrossRefPubMed
13.
go back to reference Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1996, 50: 163-170. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1996, 50: 163-170.
14.
go back to reference Friedel G, Linder A, Weigang S, et al: The surgical treatment of stage III (N2). Recent advances in lung cancer. Edited by: Carpagnano F, De Lena M. 1995, Milan: Masson, 119-127. Friedel G, Linder A, Weigang S, et al: The surgical treatment of stage III (N2). Recent advances in lung cancer. Edited by: Carpagnano F, De Lena M. 1995, Milan: Masson, 119-127.
15.
go back to reference Hata E, Miyamoto H, Tanaka M, et al: The necessity of extended systemic dissection of the regional lymph node in radical operation for lung cancer. Kyobu Geka. 1994, 47 (1): 40-44.PubMed Hata E, Miyamoto H, Tanaka M, et al: The necessity of extended systemic dissection of the regional lymph node in radical operation for lung cancer. Kyobu Geka. 1994, 47 (1): 40-44.PubMed
16.
go back to reference Detterbeck F, Kiser A, Detterbeck FC, et al: Anonymous diagnosis and treatment of lung cancer. An evidence-based guide for practicing clinicians. Edited by: Detterbeck FC, Rivera MP, Siocinski MA, et al. 2001, Philadelphia: Saunders Detterbeck F, Kiser A, Detterbeck FC, et al: Anonymous diagnosis and treatment of lung cancer. An evidence-based guide for practicing clinicians. Edited by: Detterbeck FC, Rivera MP, Siocinski MA, et al. 2001, Philadelphia: Saunders
17.
go back to reference Langendijk JA, Tjwa MK, de Jong JM, et al: Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial bracytherapy really a risk factor?. Radiother Oncol. 1998, 49 (2): 175-183. 10.1016/S0167-8140(98)00103-0.CrossRefPubMed Langendijk JA, Tjwa MK, de Jong JM, et al: Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial bracytherapy really a risk factor?. Radiother Oncol. 1998, 49 (2): 175-183. 10.1016/S0167-8140(98)00103-0.CrossRefPubMed
18.
go back to reference Phillips TL, Wharam MD, Margolis LW: Modification of radiation injury to normal tissue by chemotherapeutic agents. Cancer. 1975, 35: 1678-1684. 10.1002/1097-0142(197506)35:6<1678::AID-CNCR2820350629>3.0.CO;2-K.CrossRefPubMed Phillips TL, Wharam MD, Margolis LW: Modification of radiation injury to normal tissue by chemotherapeutic agents. Cancer. 1975, 35: 1678-1684. 10.1002/1097-0142(197506)35:6<1678::AID-CNCR2820350629>3.0.CO;2-K.CrossRefPubMed
20.
go back to reference Semenza GL: Hypoxia-induced factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev. 1998, 8 (5): 588-594. 10.1016/S0959-437X(98)80016-6.CrossRefPubMed Semenza GL: Hypoxia-induced factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev. 1998, 8 (5): 588-594. 10.1016/S0959-437X(98)80016-6.CrossRefPubMed
21.
go back to reference Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004, 22: 2184-2191. 10.1200/JCO.2004.11.022.CrossRefPubMed Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004, 22: 2184-2191. 10.1200/JCO.2004.11.022.CrossRefPubMed
22.
go back to reference Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355 (24): 2542-2550. 10.1056/NEJMoa061884. Erratum in: N Engl J Med, 2007, 356(3):318CrossRefPubMed Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355 (24): 2542-2550. 10.1056/NEJMoa061884. Erratum in: N Engl J Med, 2007, 356(3):318CrossRefPubMed
23.
go back to reference Rossi A, Maione P, Gridelli C: Cetuximab in advanced non-small cell lung cancer. Crit Rev Oncol Hematol. 2006, 59: 139-149. 10.1016/j.critrevonc.2006.02.006.CrossRefPubMed Rossi A, Maione P, Gridelli C: Cetuximab in advanced non-small cell lung cancer. Crit Rev Oncol Hematol. 2006, 59: 139-149. 10.1016/j.critrevonc.2006.02.006.CrossRefPubMed
24.
go back to reference Uflacker R, Kaemmerer A, Picon PD, et al: Bronchial artery embolization in the management of hemoptysis: technical aspects and long-term results. Radiology. 1985, 157 (3): 637-644.CrossRefPubMed Uflacker R, Kaemmerer A, Picon PD, et al: Bronchial artery embolization in the management of hemoptysis: technical aspects and long-term results. Radiology. 1985, 157 (3): 637-644.CrossRefPubMed
25.
go back to reference Rabkin JE, Astafjef VI, Gothman LN, et al: Transcatheter embolization in the management of pulmonary hemorrhage. Radiology. 1987, 163 (2): 361-365.CrossRefPubMed Rabkin JE, Astafjef VI, Gothman LN, et al: Transcatheter embolization in the management of pulmonary hemorrhage. Radiology. 1987, 163 (2): 361-365.CrossRefPubMed
26.
go back to reference Knott-Craig CJ, Oostuizen JG, Rossouw G, et al: Management and prognosis of massive hemoptysis. Recent experience with 120 patients. J Thorac Cardiovasc Surg. 1993, 105 (3): 394-397.PubMed Knott-Craig CJ, Oostuizen JG, Rossouw G, et al: Management and prognosis of massive hemoptysis. Recent experience with 120 patients. J Thorac Cardiovasc Surg. 1993, 105 (3): 394-397.PubMed
27.
go back to reference Ramakantan R, Bandekar VG, Gandhi MS, et al: Radiology. Massive hemoptysis due to pulmonary tuberculosis: control with bronchial artery embolization. Radiology. 1996, 200 (3): 691-694.CrossRefPubMed Ramakantan R, Bandekar VG, Gandhi MS, et al: Radiology. Massive hemoptysis due to pulmonary tuberculosis: control with bronchial artery embolization. Radiology. 1996, 200 (3): 691-694.CrossRefPubMed
28.
go back to reference Fernando HC, Stein M, Benfield JR, et al: Role of bronchial artery embolization in the management of hemoptysis. Arch Surg. 1998, 133 (8): 862-866. 10.1001/archsurg.133.8.862.CrossRefPubMed Fernando HC, Stein M, Benfield JR, et al: Role of bronchial artery embolization in the management of hemoptysis. Arch Surg. 1998, 133 (8): 862-866. 10.1001/archsurg.133.8.862.CrossRefPubMed
29.
go back to reference Mal H, Rullon I, Mellot F, et al: Immediate and long-term results of bronchial artery embolization for life-threatening hemoptysis. Chest. 1999, 115 (4): 996-1001. 10.1378/chest.115.4.996.CrossRefPubMed Mal H, Rullon I, Mellot F, et al: Immediate and long-term results of bronchial artery embolization for life-threatening hemoptysis. Chest. 1999, 115 (4): 996-1001. 10.1378/chest.115.4.996.CrossRefPubMed
30.
go back to reference Swanson KL, Johnson CM, Prakash UB, et al: Bronchial artery embolization: experience with 54 patients. Chest. 2002, 121 (3): 789-795. 10.1378/chest.121.3.789.CrossRefPubMed Swanson KL, Johnson CM, Prakash UB, et al: Bronchial artery embolization: experience with 54 patients. Chest. 2002, 121 (3): 789-795. 10.1378/chest.121.3.789.CrossRefPubMed
31.
go back to reference Yu-Tang Goh P, Lin M, Teo N, et al: Embolization for hemoptysis: a six-year review. Cardiovasc Intervent Radiol. 2002, 25 (1): 17-25. 10.1007/s00270-001-0047-1. Epub 2001 Nov 23CrossRefPubMed Yu-Tang Goh P, Lin M, Teo N, et al: Embolization for hemoptysis: a six-year review. Cardiovasc Intervent Radiol. 2002, 25 (1): 17-25. 10.1007/s00270-001-0047-1. Epub 2001 Nov 23CrossRefPubMed
32.
go back to reference Witt Ch, Schmidt B, Geisler A, et al: Value of bronchial artery embolisation with platinum coils in timorous pulmonary bleeding. Eur J Cancer. 2000, 36 (15): 1949-1954. 10.1016/S0959-8049(00)00188-X.CrossRefPubMed Witt Ch, Schmidt B, Geisler A, et al: Value of bronchial artery embolisation with platinum coils in timorous pulmonary bleeding. Eur J Cancer. 2000, 36 (15): 1949-1954. 10.1016/S0959-8049(00)00188-X.CrossRefPubMed
33.
go back to reference Wong ML, Szkup P, Hopley MJ: Percutaneous embolotherapy for life-threatening hemoptysis. Chest. 2002, 121 (1): 95-102. 10.1378/chest.121.1.95.CrossRefPubMed Wong ML, Szkup P, Hopley MJ: Percutaneous embolotherapy for life-threatening hemoptysis. Chest. 2002, 121 (1): 95-102. 10.1378/chest.121.1.95.CrossRefPubMed
Metadata
Title
Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy
Authors
Masami Ito
Seiji Niho
Keiji Nihei
Kiyotaka Yoh
Hironobu Ohmatsu
Yuichiro Ohe
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-27

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine